JP2020500536A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500536A5
JP2020500536A5 JP2019529995A JP2019529995A JP2020500536A5 JP 2020500536 A5 JP2020500536 A5 JP 2020500536A5 JP 2019529995 A JP2019529995 A JP 2019529995A JP 2019529995 A JP2019529995 A JP 2019529995A JP 2020500536 A5 JP2020500536 A5 JP 2020500536A5
Authority
JP
Japan
Prior art keywords
virus
nucleic acid
acid molecule
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019529995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500536A (ja
JP7788787B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064561 external-priority patent/WO2018106615A2/en
Publication of JP2020500536A publication Critical patent/JP2020500536A/ja
Publication of JP2020500536A5 publication Critical patent/JP2020500536A5/ja
Priority to JP2023115763A priority Critical patent/JP2023156294A/ja
Application granted granted Critical
Publication of JP7788787B2 publication Critical patent/JP7788787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019529995A 2016-12-05 2017-12-04 遺伝子発現増強のための組成物および方法 Active JP7788787B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115763A JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662430250P 2016-12-05 2016-12-05
US62/430,250 2016-12-05
US201762486361P 2017-04-17 2017-04-17
US62/486,361 2017-04-17
US201762587954P 2017-11-17 2017-11-17
US62/587,954 2017-11-17
PCT/US2017/064561 WO2018106615A2 (en) 2016-12-05 2017-12-04 Compositions and methods for enhancing gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115763A Division JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020500536A JP2020500536A (ja) 2020-01-16
JP2020500536A5 true JP2020500536A5 (enExample) 2020-12-10
JP7788787B2 JP7788787B2 (ja) 2025-12-19

Family

ID=61157280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529995A Active JP7788787B2 (ja) 2016-12-05 2017-12-04 遺伝子発現増強のための組成物および方法
JP2023115763A Pending JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115763A Pending JP2023156294A (ja) 2016-12-05 2023-07-14 遺伝子発現増強のための組成物および方法

Country Status (10)

Country Link
US (2) US11845939B2 (enExample)
EP (1) EP3548625B1 (enExample)
JP (2) JP7788787B2 (enExample)
KR (1) KR102655641B1 (enExample)
CN (1) CN110352247B (enExample)
AU (1) AU2017372731B2 (enExample)
BR (1) BR112019011661A2 (enExample)
CA (1) CA3045650A1 (enExample)
MX (1) MX2019006467A (enExample)
WO (1) WO2018106615A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
SG11202007606QA (en) 2018-02-17 2020-09-29 Flagship Pioneering Innovations V Inc Compositions and methods for membrane protein delivery
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20200283796A1 (en) * 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
TWI828168B (zh) * 2019-06-20 2024-01-01 愛爾蘭商健生科學愛爾蘭無限公司 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CA3171231A1 (en) 2020-03-09 2021-09-16 Sean Michael Sullivan Compositions and methods for inducing immune responses
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
KR20230009489A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
MX2022014161A (es) * 2020-05-11 2022-12-02 Janssen Pharmaceuticals Inc Vacunas contra sars-cov-2.
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3188801A1 (en) * 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
CN116802282A (zh) * 2020-07-31 2023-09-22 复制生物科学公司 经修饰的基孔肯雅病毒和辛德毕斯病毒及其用途
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
GB202020063D0 (en) * 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US20220370599A1 (en) * 2021-04-30 2022-11-24 Greenlight Biosciences, Inc. Messenger rna therapeutics and compositions
TW202313967A (zh) * 2021-07-30 2023-04-01 美商亞克圖羅斯醫療公司 Rna疫苗
GEAP202516650A (en) 2022-05-12 2025-03-10 Msd Int Business Gmbh Stabilized pre-fusion hmpv fusion proteins
WO2024057096A1 (en) 2022-09-14 2024-03-21 Ceva Sante Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
WO2024139837A1 (en) * 2022-12-27 2024-07-04 Yu Chien Hung Recombinant nucleic acids, kits comprising the same, and uses thereof in treating coronavirus infection
EP4727576A1 (en) 2023-06-14 2026-04-22 Ceva Santé Animale Self-amplifying rna expressing one or more infectious laryngotracheitis virus (ilt) antigens
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0165942A1 (en) 1983-12-23 1986-01-02 Monash University PRODUCTION OF HUMAN INTERFERON-$g(a)
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0446283A4 (en) 1988-12-01 1992-01-08 Univ North Carolina Synthetic interleukin-6
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
WO1995003777A1 (en) 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
US20020164585A1 (en) * 1998-01-16 2002-11-07 Sean Chapman Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
WO2001007613A2 (en) * 1999-07-21 2001-02-01 Large Scale Biology Corporation Method for enhancing rna or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
EP1195438A1 (en) * 2000-10-06 2002-04-10 Rijksuniversiteit te Groningen Genetic immunisation against cervical carcinoma
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
EP1397498A1 (en) 2001-05-21 2004-03-17 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Delections in arterivirus replicons
EP1278382B1 (en) 2001-07-19 2007-02-14 Telefonaktiebolaget LM Ericsson (publ) Method and apparatus for solving number portability in origin
US7204997B2 (en) 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US6943015B2 (en) * 2002-12-12 2005-09-13 Ilya Frolov Large scale production of packaged alphavirus replicons
EP1593738A4 (en) * 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
EP1651666B1 (en) 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
NZ585119A (en) 2004-03-08 2011-08-26 Ichor Medical Systems Inc Medical injector with surrounding electrical field generating penetrating electrodes
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
KR100872840B1 (ko) * 2004-07-09 2008-12-22 (주)씨아이디 돼지생식기호흡기증후군 바이러스에 대한 전체-길이의감염성이 있는 cDNA 클론 및 이의 용도
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
WO2007140522A1 (en) 2006-06-06 2007-12-13 Melbourne Health Detection and use of antiviral resistance mutations
US20120121650A1 (en) 2006-08-18 2012-05-17 Johnston Robert E Chimeric Virus Vaccines
PT3524316T (pt) 2006-10-17 2024-11-29 Inovio Pharmaceuticals Inc Dispositivos de eletroporação para eletroporação de células em mamíferos
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
WO2009056535A2 (en) 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
DK2519266T3 (da) * 2009-12-31 2017-11-06 Medigen Inc Infektiøse DNA vacciner mod Chikungunya virus
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
EA037377B1 (ru) 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
AU2012333211A1 (en) 2011-06-28 2013-12-19 Inovio Pharmaceuticals, Inc. A miniminally invasive dermal electroporation device
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Hbv聚合酶突變體
EP2814962B1 (en) * 2012-02-15 2018-07-04 CureVac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120499A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
US9956343B2 (en) 2012-12-13 2018-05-01 Panasonic Healthcare Holdings Co., Ltd. Pharmaceutical injection device
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
EP3164420A4 (en) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
KR20250108761A (ko) 2014-10-01 2025-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
JP6893177B2 (ja) 2015-05-15 2021-06-23 キュアバック アーゲー 少なくとも1つのmRNAコンストラクトの投与を含むプライムブーストレジメン(PRIME−BOOST REGIMENS)
EP4137150A1 (en) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
EP3439696A4 (en) 2016-04-06 2019-12-25 University of Washington THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
CN110612118B (zh) 2017-06-05 2024-02-13 比科尔公司 用于引起针对hbv的免疫应答的病毒样粒子
CN117866990A (zh) 2017-11-16 2024-04-12 华盛顿大学 使用HBV包膜蛋白的HBV PreS1和/或PreS2和/或S-HBsAg区域的治疗乙型肝炎病毒(HBV)的疫苗
CA3086327A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение

Similar Documents

Publication Publication Date Title
US11826416B2 (en) Induce and enhance immune responses using recombinant replicon systems
Garmashova et al. The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff
JP2023134488A5 (enExample)
JP2019530466A5 (enExample)
EP3548625B1 (en) Compositions and methods for enhancing gene expression
Gorchakov et al. Selection of functional 5′ cis-acting elements promoting efficient Sindbis virus genome replication
FROLOV et al. Cis-acting RNA elements at the 5′ end of Sindbis virus genome RNA regulate minus-and plus-strand RNA synthesis
JP2015527296A5 (enExample)
Thomas et al. Sindbis virus vectors designed to express a foreign protein as a cleavable component of the viral structural polyprotein
Anraku et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity
JP2015508648A5 (enExample)
CA2188421A1 (en) Alphavirus expression vector
JP2018186815A5 (enExample)
JP2016521539A5 (enExample)
CA2518546A1 (en) Improved alphavirus replicons and helper constructs
Jones et al. Disruption of the opal stop codon attenuates chikungunya virus-induced arthritis and pathology
CA2373300A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP2019509750A5 (enExample)
JP2024510610A5 (enExample)
Rasekhian et al. The role of 3'UTR of RNA viruses on mRNA stability and translation enhancement
Maruggi et al. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity
EP4149537A1 (en) Rna replicon encoding a stabilized corona virus spike protein
Atasheva et al. Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation
Kappes et al. Porcine reproductive and respiratory syndrome virus nonstructural protein 2 (nsp2) topology and selective isoform integration in artificial membranes
Kim et al. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype